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Low incidence of graft-versus-host disease provides themajor rational for pursuing umbilical cord blood (UCB)
stem cell transplantation (SCT). Considerable evidence also suggests a lower rate of recurrence after UCB SCT
than after transplantation from adult donors. Recent advances in understanding of the human fetal immune
development provide a rational underpinning for these clinical outcomes. The fetal immune system is geared
toward maintaining tolerance to foreign antigens, particularly to the maternal antigens to which it is exposed
throughout gestation. To this purpose it is dominated by a unique population of peripheral T regulatory cells
that activelymaintain tolerance. This and other features of the UCB lymphoid system explains the low incidence
of graft-versus-host disease and superior outcomes of UCB SCT with noninherited maternal antigenematched
grafts. At the same time, highly sensitized maternal microchimeric cells are frequently detected in UCB and
likely contribute to superior graft-versus-leukemia effects and low rates of disease recurrence in inherited
paternal antigenematched UCB recipients. However, historically erratic and slow hematopoietic recovery after
UCB SCT leads to increased early morbidity and mortality, excessive hospitalization, and increased costs. This
has held up thewidespread utilization of UCB SCT in adults. Herewe summarize recent data onUCB SCTwith an
emphasis on studies of co-infusion of adult CD34 selected hematopoietic stem cells with UCB SCT. This
procedure, through transient engraftment of adult hematopoietic stem cells, largely overcomes the problem of
delayed engraftment. It also results in predictable engraftment of a UCB with the desired characteristics. We
also brieﬂy discuss unresolved issues and possible future applications of this technology.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION party cells, hematological reconstitution after UCB stem cell
Attempts at allogeneic transplantation were reported as
early as 1957 (and among the small group of early recipients,
at least 1 received fetal rather than adult bone marrow) [1].
These early attempts faltered because of graft rejection and
graft-versus-host disease (GVHD). It was not until the
discovery of the human leukocyte antigen (HLA) system and
the recognition of its pivotal role in GVHD and graft accep-
tance that allogeneic transplantation became a feasible
procedure [2]. Initially restricted to HLA-identical sibling
pairs, it was rapidly expanded to unrelated donor trans-
plantation. Reﬁnements in HLA typing over the past decade
have led to the recognition that HLA-identical donors are
lacking for many [3]. It is estimated that only 20% of African
Americans, approximately 70% of Caucasians, and interme-
diate percentages of subjects of other ethnicities have access
to HLA-identical unrelated donors [4]. The development of
transplant methods that obviate the need for HLA identity is
therefore imperative. Umbilical cord blood (UCB) trans-
plantation has considerable promise, because of its tolerance
to the host environment and its potent graft-versus-
leukemia (GVL) effects, features that are brieﬂy summa-
rized in the light of current understanding of the fetal
immune system. When supported by co-infusion of third-edgments on page 689.
quests: Koen Van Besien, MD, PhD, Weill
f Hematology/Oncology, 520 East 70th
.cornell.Edu (K. Van Besien).
2013 American Society for Blood and Marrow
12.11.001transplantation (SCT) is fast and reliable, removing one of the
largest hurdles to successful UCB SCT.
BIOLOGICAL CHARACTERISTICS OF UCB AND
IMPLICATIONS FOR TRANSPLANTATION
The cellular composition of the UCB graft reﬂects the
functional status of the fetus at full-term gestation. UCB
contains lymphoid and dendritic cells as well as cells of
hematopoietic lineages [5,6]. In addition, many if not all UCB
units contain variable percentages of cells of maternal origin,
a phenomenon called maternal microchimerism [7-11].
Important studies over the past years (reviewed byMold and
McCune [12,13]) have led to a new understanding of the
organizationand functionof thehuman fetal immune system.
Fetal Immune System Is Geared Toward Tolerance to
Foreign Antigens
From an immunological standpoint, pregnancy repre-
sents an extraordinary situation in which both fetus and
mother are exposed to an immunologically foreign organism
[12]. In this process, the fetus develops profound and long-
lasting tolerance to antigens to which it was exposed
during gestation. Owen was the ﬁrst to observe this,
reporting on the immunological behavior of Freemartin
cattle, genetically females, but inwhom there is lifelongmale
chimerism due to transmission of cells from a male twin
during pregnancy [14]. Subsequent reports on tolerance to
tissue grafts between fraternal twins, both in humans and
other large mammals, established that tolerance to majorTransplantation.
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uterine exposure between fraternal twins who share an
intrauterine blood supply [12]. Owen and colleagues were
again the ﬁrst to show that tolerance to noninherited
maternal antigens (NIMAs) can occur during gestation when
they studied the effects of fetal exposure to Rhesus antigens
[15]. During pregnancy, rhesus-negative women often
develop anti-rhesus antibodies, the cause of hemolytic
disease of their newborns. But those women who were
daughters of rhesus-positive mothers had been rendered
tolerant during fetal life and rarely developed rhesus anti-
bodies during their own pregnancies. Claas et al. extended
this concept in a landmark 1988 article reporting that heavily
transfused and multiply sensitized adults failed to raise
antibodies to foreign HLA antigens that were present in their
own mothers (NIMA). Presumably, they had been rendered
tolerant during fetal life to these antigens [16].
The mechanisms of fetal tolerance remained long poorly
understood and were attributed to immaturity of the fetal
immune system [17,18]. But recent evidence has shown that
the fetal immune system undergoes extensive development
during gestation with waves (or so-called layers) of cells of
different phenotypic proﬁle and/or function succeeding
each other [13] (Figure 1). This model of layered immune
system development is reminiscent of the better known
model of development of the erythroid system where early
embryonic cells are replaced by cells containing fetal
hemoglobin followed by another switch at the time ofFigure 1. Model for transition from fetal to adult hematopoiesis (reproduced from Mo
of the adaptive immune system during development. Based on the linear decline in th
trimester of development, we propose that a shift in hematopoietic stem cell (HSC) id
occurs through the de novo generation of adult hematopoietic stem cells from an up
cells to adult-type hematopoietic stem cells remains unknown. Examples of different h
and after birth are listed below the ﬁgure. BM indicates bone marrow; HSPC, hematodelivery toward adult hemoglobin development. The tran-
scription factor Lin28 was recently shown to be a master
regulator of the this swith [19].
A complete description of this rapidly developing area is
well beyond the scope of this review, but data with potential
relevance to UCB SCT are summarized below. The 2 best-
studied cell populations in this regard are CD4 T cells and B1
type B cells. T regulatory cells (CD4þ, CD25þ, FoxP3þ),
dominate the fetal immune system during midgestation,
with numbers declining toward adult levels by the time of
delivery [5,20,21]. These T regulatory cells are thought to be
essential in the development of fetal tolerance to maternal
cells [12,22]. Recent work has shown that although fetal T
regulatory cells are phenotypically similar to adult cells, they
are functionally quite different and have a unique gene
expression proﬁle. Similarly, CD4þ and CD25 negative fetal T
cells are functionally different from their adult counterparts.
Complex transplant experiments support the model of
fundamentally different T cell populations in the fetus and
the adult [23]. How many fetal T cells persist at the time of
delivery and possibly even throughout childhood is still
unknown. But it is likely that the powerful suppressive effect
of fetal T regulatory cells contributes at least partially to the
suppression of GVHD reactions after UCB SCT.
B cell immunogenesis is similarly characterized by
successive generations of different B cell types. In mice, 2
types of B cells are recognized, labeled B1 and B2 cells. B1
cells (CD5þ in mice) predominate during neonatal life andld and McCune [13]). Several potential scenarios could account for the layering
e frequency of T regulatory (Treg) cells in umbilical cord blood across the third
entity from fetal to adult occurs at some point during this time. Whether this
stream progenitor cell or from a direct conversion of fetal hematopoietic stem
ematopoietic lineages that have been shown to arise during fetal development
poietic stem and progenitor cells.
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human UCB constitute about 11% of lymphocytes (as opposed
to about 4% in adults), and a very high percentage of these B
cells are CD5þ and CD27þ [24,25]. These CD27þ cells in
human UCB have recently been identiﬁed as the counterpart
of murine B1 cells [25]. B1 cells are important in innate
immunity through secretion of “natural Ig” and through their
ability to stimulate T cells. It is likely that they contribute to
innate resistance to infections [25]. The rapid proliferation of
CD5 þ B cells after UCB SCT may therefore be an important,
though still incompletely studied, component of effective
immune reconstitution.
Less is known about the ontogenesis of other components
of the fetal immune system. Umbilical cord dendritic cells are
hyporeactive upon stimulation with limited up-regulation of
surface receptors, limited signaling, and a bias against
inducing CD4 Th1 responses [5,12,26]. The preferential Th2
responses may further diminish GVHD. Fetal natural killer
(NK) cells have reduced function and cytolytic activity
compared with adult NK cells [5].
Tolerance induction is therefore the hallmark of the fetal
immune system, and at least partial persistence of the fetal
immune system in the full-term UCB contributes to the
unusually low rate of GVHD after UCB SCT despite signiﬁcant
HLA disparity and to the tolerance of NIMA antigens that has
been shown to occur after UCB SCT as was previously shown
in solid organ transplant [27]. In an initial preliminary report,
Van Rood et al. had access to a set of UCB SCT recipients with
complete HLA typing of the infant donor of the UCB unit and
of the mother of the infant [28]. Most UCB recipients were
HLA mismatched with their donors at one or several anti-
gens. In some cases, the HLA mismatch was identical to an
HLA antigen present in themother of the infant donor (NIMA
match). In other cases, the mismatched HLA antigen was not
present in the donor’s mother (no-NIMA match) (for an
example, see Table 1). They found that treatment-related
mortality and overall mortality was signiﬁcantly lower in
the recipients of NIMA-matched transplants, particularly
among recipients older than 10 years of age. Acute and
chronic GVHD were reduced among NIMA-matched trans-
plant recipients, but this reduction was not statistically
signiﬁcant. Neutrophil engraftment was more rapid among
NIMA-matched recipients, and, somewhat surprisingly, there
was also a trend toward lower relapse rate in the NIMA-
matched patients.
The effect of NIMA matching on transplant-related
mortality (TRM) was recently conﬁrmed in a study whereTable 1
Examples of NIMA Match versus NIMA Mismatch
Recipient A1 A24 B7 B65 DR0102 DR1501
NIMA match
CB unit 1 A2 A24 B7 B65 DR0102 DR1501
Mother of unit 1 A1 A24 B57 B65 DR0102 DR1305
NIMA mismatch
CB unit 2 A2 A24 B7 B65 DR0102 DR1501
Mother of unit 2 A3 A24 B7 B65 DR0102 DR1501
In this example, 2 identical 5/6 HLA-matched cord blood units are evaluated
for use in a particular recipient. The mismatch between UCB recipient and
donor is in the HLA-A locus. UCB recipient HLA-A1 and CBU HLA-A2. Case 1
NIMA match: The mother of CBU1 happens to have HLA-A1. During gesta-
tion, CBU was therefore exposed to HLA-A1 and has become tolerant to
NIMA HLA-A1. Case 2 NIMA mismatch: The mother of CBU2 does not have
HLA-A1. This CBU was therefore never exposed to HLA-A1 and has not
become tolerant to it. All things being equal, transplantation with CBU1 is
expected to have superior outcome.the outcome of 48 NIMA-matched UCB SCTs was compared
with that of 116 noneNIMA-matched UCB SCTs in a case-
control fashion [29]. The groups were matched for impor-
tant covariates. No effect of NIMA matching on relapse rate,
acute or chronic GVHD, or neutrophil recovery was found in
this more recent analysis. But TRM was lower after NIMA-
matched UCB SCTs compared with NIMA-mismatched UCB
SCTs (relative risk, .48; P ¼ .05; 18% versus 32% at 5 years).
Consequently, overall survival was higher after NIMA-
matched UCB SCT. The 5-year probability of overall survival
was 55% after NIMA-matched UCB SCTs versus 38% after
NIMA-mismatched UCB SCTs (P ¼ .04). Of note, the impor-
tance of NIMA matching may also extend to the setting of
adult haploidentical transplantation. Two groups have
shown that transplant from a NIMA-matched haploidentical
donor is associated with improved outcome, mainly because
of a lower incidence of GVHD [30,31].
Maternal Microchimerism in the UCB May Be Responsible
for GVL
Several observations point to a reduced rate of disease
recurrence after allogeneic cord blood transplantation
compared with adult-related or -unrelated donor trans-
plantation. This was initially revealed in double UCB SCT,
which has been shown to have lower recurrence rates
compared with adult transplant [32,33] (though the beneﬁt
of reduced rates of recurrence was largely offset by increased
early TRM after UCB SCT). In some studies, similar low
relapse rates have been observed after single UCB SCT
[32,34]. Some have attributed the increased GVL effects after
UCB SCT to increased mismatching [35,36]. Indeed, prelimi-
nary evidence in children shows that more mismatching
decreases the risk of disease recurrence. This mechanism
could explain why relapse rates after UCB SCT are lower than
those after transplant from HLA-identical donors. But hap-
loidentical adult grafts are even more HLA mismatched than
UCB. Yet, in several studies, haploidentical SCT is associated
with higher rates of disease recurrence [37,38]. Others have
proposed that killer cell immunoglobulin-like receptor (KIR)-
ligand mismatching after UCB SCT may be associated with
reduced relapse risk [39]. Although this may be correct, KIR
antigen mismatching is also frequent in matched related and
unrelated donor SCT, and KIR mismatching does not explain
the differential relapse rates with these graft sources.
More recently, Van Rood et al. proposed a hypothesis
based on the observation of frequent maternal micro-
chimerism in the graft [40]. It has been known for decades
that maternal cells can cross the placenta and colonize the
fetus and vice versa (for review see Mold and McCune [12]).
These cells are most prevalent during midgestation but can
also be frequently detected in UCB. In contrast to the fetal
immune system that invariably becomes tolerant to NIMAs,
the maternal immune system becomes sensitized to the
paternal HLA antigens inherited by the fetus (the inherited
paternal antigens [IPA]). This phenomenon is the frequent
cause of anti-HLA antibodies in parous women that can
complicate platelet transfusions and contribute to graft
rejection in stem cell and organ transplantation [41-43].
Because sensitized maternal cells are present in virtually all
UCB, van Rood et al. reasoned that the small number of
maternal cells rather than the majority of fetal lymphoid
cells are primarily responsible GVL effects after cord blood
transplant. In an ingenious analysis, they compared the
outcome of two sets of patients undergoing UCB SCT. In most
cases, there was an HLA mismatch between the mother of
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mother was sensitized. They labeled this donorerecipient
combination “shared IPA transplants.” In some cases,
labeled “no-shared IPA transplants,” there was no IPA target
in the recipient. This can happen when father and mother of
the fetus share an HLA haplotype (for an example, see
Table 2); this fetus can be HLA identical or nearly HLA
identical to the mother. In other cases, the HLA-mismatch
between recipient and cord blood was such that the IPA
targets were absent in the recipient. The recurrence rate
was signiﬁcantly lower in shared IPA transplants than in
no-shared IPA transplants, presumably because of the anti-
IPA mediated GVL effects in the IPA transplants. This study,
although retrospective and with several limitations, provides
a powerful and rational explanation for maternally mediated
GVL effects in UCB SCT. It will be up to future investiga-
tors to prospectively validate these observations. Interest-
ingly, in pediatric recipients of parental haploidentical T
celledepleted SCT, there is a much better outcome in
patients receiving SCT from themother compared with those
receiving paternal SCT, probably because mothers have been
previously sensitized to the child’s IPAs [44].
Hematopoietic Potential of UCB: Comparison with Adult
Stem Cells
Stem cells and progenitor cells are present in UCB, at
a much higher concentration than in adult peripheral blood
and in concentrations that may exceed even those of adult
bone marrow [6,45]. The phenotypic characteristics of UCB
and adult bonemarrow cells are remarkably similar however
[46], with the exception of a higher density of expression of
CD34 on the cells and an increased expression of HLA DR on
neonatal cells. Functionally, UCB has a higher proportion of
cells with stem cell characteristics, including the ability to
replate and expand while maintaining primitive character-
istics. They are also more proliferative in long-term cultures
and have increased migration capacity. Finally, in contrast to
adult bone marrow cells, they are less dependent on ex-
ogenous cytokines for establishing growth in SCID mouse
models [47].
The mechanisms underlying the proliferative and
expansive advantage of UCB over adult hematopoietic stem
cells include longer telomere length, more rapid exit fromTable 2
Example of IPA Targeting versus No IPA Targeting by Maternal
Microchimerism
Recipient A1 A24 B7 B65 DR0102 DR1501
IPA targeted
CB unit 1 A2 A24 B7 B65 DR0102 DR1501
Mother of unit 1 A1 A24 B57 B65 DR0102 DR1305
Not IPA targeted
CB unit 2 A2 A24 B7 B65 DR0102 DR1501
Mother of unit 2 A3 A24 B7 B65 DR0102 DR1501
In this example, the same identical 5/6 HLA-matched CBUs are evaluated for
use in the same recipient. The mismatch between UCB recipient and donor
is in the HLA-A locus. UCB recipient HLA-A1 and CBU HLA-A2. Case 1 IPA
targeting: During gestation, microchimeric maternal cells of CBU1 were
sensitized to paternal HLA-B7 and HLA-DR 1501. These same IPA antigens
are present in the recipient and are therefore targets of GVL activity. Case 2
No IPA targeting: The mother of CBU2 happens to be homozygous to her
child in HLA-B and HLA-DR. Therefore, exposure to HLA-B7 and HLA-
DR1501 did not, in this case, lead to sensitization of maternal micro-
chimeric cells. All things being equal, transplantation with CBU1 is expected
to have superior outcome due to more potent GVL effects. This also illus-
trates how one can simultaneously select UCB units to be NIMA matched
and IPA targeted.G0/G1 into the cell cycle, increased cytokine sensitivity,
and/or paracrine cytokine effects. Gene expression analysis
shows considerable differences in gene expression patterns
between adult bone marrow and UCB, with fetal gene
expression regulated by the transcription factor Sox17 [48].
In murine competitive repopulation experiments, fetal or
newborn blood tends to outcompete adult bone marrow
competitors [49]. Rosler et al. directly compared the hema-
topoietic potential of human adult and fetal hematopoietic
stem cells in an SCID HU model [50]. For this purpose,
immunodeﬁcient disease (SCID) mice were implanted with
human fetal bones. HLA-mismatched CD34 selected cells
from 2 human donors were injected simultaneously and 8 to
10 weeks later engraftment of myeloid and lymphoid cells
was analyzed. Both adult bone marrow CD34 cells and cord
blood CD34 cells could routinely engraft and differentiate
into myeloid and B-lymphoid cells in this assay. After 8 to 10
weeks, they accounted for approximately 50% of cells circu-
lating in the animals. When cord blood and adult bone
marrow were injected simultaneously, the engraftment of
cord blood cells was markedly superior to that of adult bone
marrow cells. Cord blood engraftment was detected in 10 of
10 animals. Adult cells were detected in only 5 of 10 animals,
and even in those, the adult cells constituted only a small
fraction, less than 10% of all myeloid and B cells.
Although hematopoietic stem cell characteristics of UCB
favor long-term dominance, other work has shown that rate
of engraftment is determined by the number of hematopoi-
etic stem cells transplanted [51]. In clinical practice, the usual
measure of hematopoietic stem cells is the number of CD34þ
cells in the graft. UCB grafts contain at least 1 log fewer
CD34þ cells than adult CD34þ stem cell grafts. The low
number of hematopoietic stem cells in UCB grafts explains
the often slow and erratic hematopoietic recovery.
CLINICAL UCB SCT: OVERCOMING LIMITATIONS
The ﬁrst UCB SCT was reported in 1989, and since then
extensive experience has accrued with UCB SCT using both
related and unrelated donors. Multiple aspects of this
experience have been reviewed extensively by others
[52-54]. Here, we only brieﬂy summarize those data with an
emphasis on novel developments and areas of controversy. It
is now well accepted that UCB SCT can result in durable
engraftment and cure of leukemia. The incidence of acute
and chronic GVHD is relatively low despite extensive HLA
mismatching between donor and recipient [35]. Still, even
though mismatching is much better tolerated with UCB SCT
compared with adult mismatched SCT, matching cannot be
completely ignored. Better matching grafts tend to produce
better long-term outcomes, and recent data suggest that
HLA-C matching further improves outcomes, particularly
among recipients that are 5/6 or 6/6matched at HLA A, B, and
DR [55]. There is also considerable evidence that UCB SCT,
particularly double UCB SCT, has a lower recurrence rate than
adult SCT. For example, the group fromMinnesota compared
the outcomes of myeloablative conditioning followed by
double UBC SCT, matched related, matched unrelated, and
mismatched unrelated transplants for adults with hemato-
logical malignancies [33]. The risk of relapse was only 15% of
recipients of double UCB (95% conﬁdence interval, 9%
to 22%), signiﬁcantly lower than in recipients of matched
related donor SCT (43%; 95% conﬁdence interval, 35% to 52%),
adult matched unrelated donor SCT (37%; 95% conﬁdence
interval, 29% to 46%), or adult mismatched unrelated donor
SCT (35%; 95% conﬁdence interval, 21% to 48%). Similarly, in
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recurrence rates were considerably lower after double UCB
SCT [32]. Verneris et al. [32] suggested that the reduced rate
of recurrence was limited to recipients of double UCB SCT
versus single UCB SCT. Other investigators did not conﬁrm
this. A recently reported randomized study failed to show
an advantage to double UCB SCT over single UCB SCT in
children [33].
The limitations of UCB SCT are also increasingly clear and
relate mostly to graft failure/rejection or delayed engraft-
ment. Closely associated with this are the prolonged length
of stay, increased expense, and increased TRM after UCB SCT
[56,57]. Several groups reported an association between the
presence of donor-speciﬁc antibodies (DSA) and graft rejec-
tion in HLA-mismatched transplant and particularly in cord
blood transplant [42,43,58-60], but there is considerable
debate over the relative importance of this ﬁnding [61], over
the exact mechanisms by which this occurs, and over the
management of transplant patients with positive DSA
[62,63]. For many transplant programs, there is now sufﬁ-
cient evidence to avoid grafts that are targeted by DSA [64].
Another area of debate centers on UCB quality and its
assessment. As best studied by the Sloan-Kettering group, it
is clear that occasional cases of graft failure are due to poor
graft quality [65,66]. Further investigations are required to
understand the best determinants and measures of cord
quality to ensure engraftment. For an extensive discussion of
this topic, we refer to the recent review by Barker et al. [65].
Less widely debated is the issue of study endpoints and
determinants of success. UCB studies typically focus on
engraftment, usually deﬁned as the ﬁrst of 3 consecutive
days of neutrophil recovery of absolute neutrophil count
(ANC) > 0.5  109/L. This may not be the best endpoint for
studies. In consecutive studies, the Seattle group has shown
that time to achievement of an ANC > 0.1  109/L is better
correlated with survival after allogeneic transplant, regard-
less of graft type, and that TRM rapidly increases if this
milestone is not reached by day 16 [67,68]. Rather than
focusing on the median time to neutrophil recovery, it may
therefore be advisable in future studies to report the
percentage of patients achieving an ANC> 0.1109/L by day
16. Unfortunately, this measure is not readily available in US
labs, because differential counts are not usually performed in
patients with ANC < 0.5  109/L. Platelet recovery is another
very important determinant of long-term outcome. Delayed
platelet recovery is associated with increased length of stay
and increased expense, and in some studies it is an important
correlate of TRM [56,57,69]. Platelet recovery after UCB SCT
tends to be much more delayed than that after adult
transplantation.
ENHANCING HEMATOPOIETIC RECOVERY AFTER UCB SCT
Initial efforts at improving outcomes of UCB SCT
addressed the issue of cell dose by infusing several products
[70,71]. Before double UCB, many patients were ineligible for
UCB SCT because of lack of UCB units that were both well
enough matched and had an acceptable cell number. The
problem was particularly dire among African American
patients. There is obviously some genetic clustering; as
a result UCB fromAfrican American newborns tends to be the
best match for African American recipients, but UCB from
African American infants on average contains considerably
fewer nucleated cells [72]. By combining UCB units, an
acceptable cell number could be reached. Though hemato-
poietic recovery remains unpredictable and often slow,transplantation could now be offered most patients in need.
It is now well established that in most cases only one of the
UCB units ensures durable engraftment. What biological
characteristic, if any, determines the winner graft remains
a topic of debate [73,74].
Much effort has been devoted to expansion of UCB stem
cells or subsets of such cells. This ﬁeld has the promise of
tissue engineering with generation of cell types of particular
interest that potentially could be further manipulated
in vitro to generate improved antileukemic effects [75]. As far
as cord blood is concerned, the primary goal of most trials is
to enhance hematopoietic recovery. Several excellent
reviews have summarized this ﬁeld [76,77]. Although faster
than expected hematopoietic recovery has been observed,
this does not occur reliably. In some studies, expanded UCB
has been infused with nonexpanded cells from another
donor; in such cases, durable engraftment is almost univer-
sally derived from the nonexpanded cord. No study or
expanded UCB has yet been able to show any impact on
platelet recovery. An additional hurdle for UCB expansion is
the time required for generating a sufﬁcient number of cells
to ensure rapid recovery. This is expected to take several
weeks, a time period not always permissible because of the
aggressive nature of many hematological malignancies. To
circumvent this problem, efforts are ongoing to develop “off
the shelf” products that might provide transient hemato-
poietic support.
CO-INFUSION OF ADULT PROGENITOR CELLS WITH UCB
STEM CELLS
A technically less-demanding approach consists of the
infusion of UCB cells with cytokine mobilized CD34þ
selected donor peripheral blood stem cells from an adult,
usually a mismatched relative. Fernandez et al. reported 3
patients with advanced hematological malignancies who
underwent UCB SCT after myeloablative conditioning sup-
ported by co-infusion of adult haploidentical CD34þ cells
[78]. In all patients, adult donor hematopoiesis was tran-
siently detected and caused rapid count recovery but
disappeared over time. The same group has since performed
87 such transplants, and detailed results were reported on
the 55 initial patients [79,80]. Four other groups have re-
ported outcomes of cord blood transplant supported by
co-infusion of adult, usually haploidentical cells [81-84]. As
of July 2012, data on 206 patients have been presented and
are summarized in Table 3.
In all studies, the adult donor cells were T cell depleted,
usually by a CD34 selection process. In all studies, antithy-
mocyte globulin (ATG) was part of the conditioning regimen,
further T cell depleting the adult donor and, as a secondary
effect, also depleting the cord blood unit. But there were also
major differences. The National Institutes of Health study
was restricted to young patients with severe aplastic anemia
[82], They used a nonmyeloablative conditioning regimen.
They were the only group to use equine ATG as part of the
conditioning regimen (as opposed to rabbit ATG in all other
studies). The Utrecht group in the Netherlands treated
children, most of whom had metabolic disorders [83]. The
largest experiences come from the Madrid group and from
the University of Chicago [80,84,85]. Both studies treated
adults with hematological malignancies. The patients in
Chicago were 15 years older (median age, 51 versus 34 years)
and more often had advanced hematological malignancies.
The Spanish group used myeloablative conditioning, and the
Chicago group used a ﬂudarabine melphalan regimen. GVHD
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K. Van Besien et al. / Biol Blood Marrow Transplant 19 (2013) 682e691 687prophylaxis consisted of calcineurin inhibitors combined
with steroids in Spain and combined with mycophenolate
mofetil in Chicago. Infection prophylaxis varied, with very
intensive cytomegalovirus (CMV) prophylaxis routinely used
in Chicago [86,87].
There were also differences in donor selection proce-
dures. Most adult donors were haploidentical relatives, but
approximately one-third of the Spanish patients received
cells from completely mismatched unrelated donors. Cord
blood selection procedures were similar, although the
Chicago group allowed a lower UCB cell dose (average of
1.6  107 nucleated cells/kg recipient weight).
Regardless of the patient and donor selection or proce-
dural differences, all groups observe rapid neutrophil
recovery with a median time of 10 to 11 days (Figure 2). This
early hematopoietic recovery is almost invariably generated
by the adult graft. Median time to platelet recovery was also
faster than what is generally reported after UCB SCT and
ranged from 19 days in Chicago to 32 days in Madrid
(Figure 3) (compared with 38 days after reduced-intensity
conditioning and double UCB SCT in Minnesota) [57]. In
most patients, initial hematopoiesis is over time replaced by
UCB-derived hematopoiesis (Figure 4). Occasional failures of
the UCB graft or of both grafts were observed in all series. In
some cases, graft failure was associated with DSA. UCB graft
failures were occasionally attributed to poor cord blood
viability [85]. Of note, in the Chicago experience, an excessive
dose of adult haploidentical CD34 cells was associated with
decreased UCB engraftment. The Madrid group addressed
cord failures by infusion of a second UCB unit, which tended
to engraft and outcompete the residing adult graft. In other
centers, the adult graft was left unchallenged after cord
blood failure. Such patients, a minority, had a high incidence
of relapse and opportunistic infections [84,85]. The data from
the National Institutes of Health are particularly provocative.
Until recently, the outcome of UCB SCT was disappointing
for patients with severe aplastic anemia. In their series, 11 of
12 heavily transfused patients engrafted and had durable
responses [82].
Other outcomes varied considerably; the incidence
of opportunistic infections, particularly CMV disease and
toxoplasmosis, was considerable in the Spanish cohort but
much less in other cohorts. This difference may be due to
differences in infection prophylaxis, particularly CMV
prophylaxis and in GVHD prophylaxis and treatment. The
routine use of steroids for GVHD prophylaxis as practiced in
Madrid may result in an increased propensity for infectious
complications. Cases of Epstein-Barr virus (EBV) reactivation
and EBV posttransplantation lymphoproliferative disease
were observed in all series, and close monitoring and pre-
emptive treatment for this complication is warranted.
Incidence and severity of GVHD was generally low. In the
Madrid series, there were 6 cases of grade III to IV acute
GVHD out of 55 recipients. None was observed in the other
centers. There were 3 cases of extensive chronic GVHD in
Spain but none in the other centers. Despite this low inci-
dence of severe GVHD, the relapse rates for those with
malignant disease were moderate. The cumulative incidence
of recurrence was 17% at 1 year in Spain and 28% in Chicago.
Long-term immune reconstitution was studied by
the Chicago group and by the Madrid group. The Chicago
group assessed lymphocyte subsets, T cell diversity, Cylex
Immuknow assay ([Cylex, Columbia, MD] a measure of T cell
responsiveness), and serological response to pneumococcal
vaccination [88]. NK cell and B cell reconstitution were
Figure 2. Time to neutrophil engraftment: results from (A) Madrid and (B) Chicago (reproduced from Sebrango et al. [94] and Liu et al. [84]). ANC-500 indicates time
to neutrophil count of 500; CB ANC-500, time to achieve 500 neutrophils from the UCB graft; CB full chimerism, time to full cord blood chimerism.
K. Van Besien et al. / Biol Blood Marrow Transplant 19 (2013) 682e691688extremely rapid, occurring at 1 month and 3 months,
respectively. T cell recovery was delayed with a gradual
increase in the number of T cells, starting around 6 months
posttransplantation, and was characterized by a diverse
polyclonal Tcell repertoire. Recoveryof immunoglobulins and
responsiveness to pneumococcal vaccination was observed.
T cell spectratype was often remarkably diverse. The authors
concluded that immune reconstitution after haplocord
transplantation was similar to that seen after cord blood
transplantation, despite infusion of much lower cord blood
cell doses.
The Madrid group reported similar observations in their
patients [89]. NK and B cells recovered to normal or higher
than normal by 1 and 2 months, respectively. Recovery of T
cells was slower. Serial analyses of signal joint T cell receptor
excision circles showed very low levels by the third month
after CBT, followed by recovery to levels persistently similar
or higher than those observed before transplantation and in
normal control subjects. In both the Chicago (Figure 4) andFigure 3. Time to platelet recovery. (A) Madrid cumulative incidence of platelet cou
count >20,000/mL (reproduced from Sebrango et al. [94] and Liu et al. [84]).Madrid series, early T cell recovery was derived from the
adult donor followed by gradual replacement by cells of
UCB origin. It is likely that most of the early B cells after
haplocord transplant are also UCB derived. Of interest, the
National Institutes of Health group observed immediate
UCB-derived T cell reconstitution, without detectable adult
donorederived T cells at any time point. This strikingly
different kinetic proﬁle of immune reconstitution may be
due to the use of a different formulation of ATG. Nobody has
evaluated the origin of NK and B cells.
CONCLUSION, OPPORTUNITIES, AND UNRESOLVED
ISSUES
The characteristics of the umbilical cord grafts include
potent hematopoietic potential and an immune system
dominated by effectors of peripheral tolerance, but also
by the presence of microchimeric maternal cells that are
routinely sensitized to the recipient. These biological features
help to explain the ability of UCB cells to outcompete adultnt >20,000/mL and >50,000/mL. (B) Chicago cumulative incidence of platelet
Figure 4. Evolution of chimerism in the Chicago series. (A) Unfractionated peripheral blood cells. (B) CD3 cells (reproduced from Liu et al. [84]).
K. Van Besien et al. / Biol Blood Marrow Transplant 19 (2013) 682e691 689grafts and cause minimal GVHD while exerting GVL effects
that are most likely due to maternal cells. Future research
may provide further evidence of these mechanisms, partic-
ularly of the GVL effects exerted bymaternal cells. At present,
these features provide a compelling rationale to continue
clinical research to optimize the use of this unique stem cell
source.
Slow and erratic hematopoietic recovery is the Achilles
heel of UCB SCT and has prevented more widespread use in
adults. It causes a heightened incidence of early mortality,
prolonged length of hospital admissions, and signiﬁcant
costs. Co-infusion of adult cells as described here is the ﬁrst
method that is readily applicable and results in reliable and
clinically relevant improvements in hematopoietic recovery.
Highly encouraging results are now available from 4 centers
with over 200 patients undergoing transplantation.
There are many opportunities for further development
of this technology. For example, cord blood selection algo-
rithms are currently heavily weighted toward maximizing
cell doses at the expense of HLA matching. But our data
suggest that for haplocord SCT, UCB cell dose has no effect on
outcome. It should thus be possible to select cords based on
other criteria that may be more important for long-term
outcomes, such as HLA matching, NIMA matching, IPA
targeting, or even KIRmismatching. In contrast to double UCB
SCT, the selected graft will reliably be the “winner”. This
concept will require prospective validation but, if conﬁrmed,
will have signiﬁcant potential to improve long-term
outcomes.
There is also the possibility of using haplocord SCT to
support the infusion of rare cell populations that have
important therapeutic implications. For example, haplocord
transplant has already been used in the transplantation of an
HIV-positive leukemia patient, where the UCB donor was
CCR5 delta 32 mutated and therefore resistant to HIV [90]. At
least in theory, this approach could also be used for trans-
planting genetically modiﬁed UCB cells or to support trans-
plantation for sickle cell disease.
Many questions and issues remain to be resolved, some
of which are brieﬂy discussed. Graft rejection or failure has
occurred in each series and constitutes a considerable
risk. The quality and assessment of cord blood products is
under continuing debate, and standards are developing.Adhering to rigorous standards of viability as proposed by
the Sloan-Kettering group may prevent some issues. DSA
have also recently been identiﬁed as risk factors for graft
rejection, and exposure of the graft to DSA should be avoided
if possible. Finally, very little is known about the interplay
between adult hematopoietic and UCB cells. The group from
Chicago found a correlation between adult graft CD34 dose
and persistence of the adult graft. Though very preliminary,
these data are intriguing and suggest that the balance
between UCB and adult graft could be manipulated by
varying the adult cell dose (and possibly its composition).
Unresolved questions also linger around the choice of the
adult donor and its fate. Is there a beneﬁt to using related
donors? Or might a totally mismatched adult, as the Spanish
group has utilized in one-third of their patients, be preferred
for a temporary graft as this may enhance the likelihood of
the cord blood unit predominating? Do such donors cause
more complications or, to the contrary, could they be
selected in a fashion to optimize GVL effects (eg, by KIR
mismatching)? Is T cell depletion necessary for the adult
donor or would it be outcompeted by the umbilical cord,
even if were infused without manipulation? Data in this
regard are extremely limited. Is the adult graft destined to
irreversibly and completely disappear, or are there residual
adult donor cells that persist in the blood or other recipient
organs? And if so, what is their function, if any? In the Chi-
cago series, a small fraction of residual adult donor T cells
were often detected in the blood.
Other questions pertain to the conditioning regimen and
particularly to the use of ATG, which has been part of
every protocol but also contributes to some of the side
effects, particularly to EBV reactivation [91]. One wonders
whether ATG could be omitted or replaced by other agents
with less risk for EBV reactivation, for example, by alemtu-
zumab [92]. The further development of this and other
related transplantation procedures, combined with parallel
advances in diagnostics and supportive care, may ﬁnally
fulﬁll the promise of a donor for all [93].
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